Pancreatic adenocarcinoma: A review of recent paradigms and advances in epidemiology, clinical diagnosis and management

Table 4 Studies showing the role of neoadjuvant chemotherapy and chemoradiotherapy in resectable pancreatic adenocarcinoma

Ref.	Type of study	Type of neoadjuvant therapy	Drugs	Results
Tajima et al[177], 2012	Retrospective pilot study	Chemotherapy	Gemcitabine and S1	The 3 yr survival rates of NACT group (55.6%) was higher than control group (29.6%)
O’Reilly et al[178], 2014	Phase II trial non randomized	Chemotherapy	Gemcitabine and oxalipaltin	Resectability was 71%
				Overall survival was 21.7 mo
Motoi et al[179], 2013	RCT- NACT vs direct surgery	Chemotherapy	Gemcitabine and S1	Results awaited
Scott et al[180], 2017	RCT- NACT vs direct surgery	Chemotherapy	FOLFIRINOX	Results awaited
Labori et al[181], 2017	RCT- NACT vs direct surgery	Chemotherapy	FOLFIRINOX	Results awaited
Heinrich et al[182], 2011	RCT- NACT vs direct surgery	Chemotherapy	Gemcitabine and oxalipaltin	Results awaited
Sohal et al[183], 2017	RCT-FOLFIRINOX vs GnP	Chemotherapy	FOLFIRINOX vs Gemcitabine and nab paclitaxel	Results awaited
Turrini et al[184], 2009	Prospective study	Chemoradiotherapy	5-Flurouracil and cisplatin with radiotherpay	Respectability rate is 82.6%
				Median overall survival for resected patients is 23 mo
Golcher et al[185], 2015	RCT- NACRT vs direct surgery	Chemoradiotherapy	Gemcitabine and Cisplatin with radiotherpay	R0 resection rate (52%) and median overall survival after tumor resection (27 mo) was greater NACRT arm
Okano et al[186], 2017	Prospective study	Chemoradiotherapy	S-1 with radiotherapy	1-yr and 2-yr survival rates are 91% and 83% in resectable group

RCT: Randomized control trial; NACT: Neoadjuvant chemotherapy; NACRT: Neoadjuvant chemoradiotherapy; FOLFIRINOX: 5-Flurouracil, irinotecan and oxaliplatin.